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Min Zhang*† and Douglas E. Schaubel
In settings where a randomized trial is infeasible, observational data are frequently used to compare treatment-
specific survival. The average causal effect (ACE) can be used to make inference regarding treatment policies on
patient populations, and a valid ACE estimator must account for imbalances with respect to treatment-specific
covariate distributions. One method through which the ACE on survival can be estimated involves appropri-
ately averaging over Cox-regression-based fitted survival functions. A second available method balances the
treatment-specific covariate distributions through inverse probability of treatment weighting and then contrasts
weighted nonparametric survival function estimators. Because both methods have their advantages and dis-
advantages, we propose methods that essentially combine both estimators. The proposed methods are double
robust, in the sense that they are consistent if at least one of the two working regression models (i.e., logistic model
for treatment and Cox model for death hazard) is correct. The proposed methods involve estimating the ACE
with respect to restricted mean survival time, defined as the area under the survival curve up to some prespeci-
fied time point. We derive and evaluate asymptotic results through simulation. We apply the proposed methods
to estimate the ACE of donation-after-cardiac-death kidney transplantation with the use of data obtained from
multiple centers in the Netherlands. Copyright © 2012 John Wiley & Sons, Ltd.
Keywords: average causal effect; Cox regression; double-robust estimator; inverse weighting; right censoring;
restricted mean lifetime
1. Introduction
Observational data are frequently used to compare treatment-specific survival in settings where a ran-
domized clinical trial is infeasible. Even in cases where a randomized trial to compare treatments is
feasible, observational studies may be an attractive alternative because much greater sample sizes can be
obtained at considerably less cost and effort. Methods applicable to observational data include those
which accommodate imbalances with respect to the treatment-specific distributions of pretreatment
patient characteristics. Covariate adjustment may also be desired for randomized trials, to adjust for
chance imbalances in adjustment factors and perhaps to increase precision.
Despite the value of observational studies, the randomized trial rightfully serves as the gold standard.
This has important implications from at least two angles. First, in analyzing observational data, one is
motivated to compute an estimator whose target (e.g., difference in treatment-specific means) would
be obtained in the setting where treatment was randomized. Second, there is an incentive to estimate
quantities that would be estimated in the context of a randomized trial. For example, in the case of
censored survival data, the analysis of data from a randomized trial would likely consist of plots of
treatment-specific Kaplan–Meier or Nelson–Aalen survival curves. Survival probability is easily intuited
by nonstatisticians. A related measure is the area under the survival curve. In particular, if T represents
failure time with survival function, P.T > t/D S.t/, then mean survival time is equal to the area under
the entire survival curve, given by EŒT  D
R1
0 S.t/dt . The most popular methods of estimating S.t/
in settings where covariate adjustment is unnecessary are nonparametric; that is, the aforementioned
Kaplan–Meier [1] and Nelson–Aalen methods. In cases where covariate effects are modeled, the
Cox [2] model (a semiparametric approach) has dominated the hazard regression applications in the
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biomedical literature almost since its inception. The nonparametric aspects of each of the three aforemen-
tioned methods result in inference that is restricted to the .0;  time interval, where  is the maximum
observation time. Although mean survival time may be of most inherent interest, because inference is on
a restricted range anyway, restricted mean lifetime, EŒminfT;LgD
R L
0
S.t/dt , is a useful and practical
alternative metric; for example, see [3–9]. Restricted mean lifetime has a straightforward interpretation
(i.e., expected number of time units lived out of the next L) and is the measure of interest in this report.
With respect to restricted mean lifetime, the average causal effect (ACE) is the area between the
average treatment-specific survival curves (out to t D L), with the averaging (for both treatments) being
with respect to the marginal covariate distribution. As will be explicitly developed later, this quantity
is the same as the area between the unadjusted treatment-specific survival curves in the setting of a
randomized study. There are different ways to estimate the pertinent treatment-specific average survival
functions. Various authors have advocated fitting Cox models, then explicitly averaging over fitted sur-
vival curves (e.g., [3, 5, 10]). An alternative method involves inverse probability of treatment weighting
(IPTW) [11–15]. In IPTW, each subject is weighted by the inverse of the probability of being assigned
the treatment they actually received. The weighted treatment-specific samples have a covariate distribu-
tion that equals that of the margin (across both treatments). Hence, differences between integrated IPTW
versions of nonparametric estimators serve as estimators of the ACE of restricted mean lifetime. For
example, Hubbard et al. [16] developed IPTW methods to contrast survival curves, whereas Wei [15]
proposed various measures based on S.t/ with the use of the IPTW method, including restricted mean
lifetime. Instead of inverse probability weighting, a popular alternative is to match by the probability of
being treated [17, 18], which we do not consider in this article.
In this report, we propose a semiparametric double-robust estimator of the ACE on restricted mean
lifetime. The proposed method can be viewed as a hybrid of the approaches of Chen and Tsiatis [10] and
Wei [15]. A logistic model is assumed for treatment assignment, and a Cox model is used for the death
hazard conditional on treatment and the adjustment covariates; both are working models. The proposed
methods are double robust in the sense that consistent estimation of the ACE is obtained if at least one
of the two working models is correct [19–21].
The data that motivate our methods originate from a multicenter study of kidney transplant patients
from the Netherlands [22]. The practice of transplanting kidneys from deceased donors following cardiac
death (so-called donation-after-cardiac-death (DCD) kidneys) is controversial. The practice happens to
be much more frequent in the Netherlands than other parts of the world (e.g., the USA). We sought to
estimate the ACE of DCD kidney transplantation versus its alternative, which we refer to collectively as
non-DCD transplantation.
We organize the remainder of this report as follows. In the next section, we formalize the ideas outlined
previously and describe the proposed methods and corresponding asymptotic properties. We assess the
finite-sample applicability of the procedures through simulation in Section 3. We then use the proposed
methods in Section 4 to analyze the kidney transplant data described previously. Section 5 concludes the
report with some discussion.
2. Method
Suppose we are interested in comparing two groups, with group denoted by A (with AD 0 or 1) in terms
of the mean of the restricted lifetime up to timeL. If we denote the survival time by T , then the restricted
lifetime is defined as min.T; L/ and the restricted mean lifetime can be represented as Efmin.T; L/g.
In the setup we consider in this article, treatment groups are not randomized, and therefore some sort
of adjustment for imbalance in baseline covariates, Z, is required. As in almost all studies involving
time to an event, survival time is subject to right censoring, denoted by C . We assume that censor-
ing is conditionally independent of death time given treatment; that is, T ?? C jA, an assumption that
we discuss further in Section 5. We define the observed possibly censored lifetime as U D min.T; C /
and the indicator for not being censored as  D I.T 6 C/. The observed data for each subject i are
.Ai ; Zi ; Ui ; i /, which are assumed to be independent and identically distributed across i D 1; : : : ; n.
We denote the observed counting process of event and the at-risk process by Ni .t/D I.Ui 6 t; i D 1/
and Yi .t/ D I.Ui > t /, respectively. For simplicity of presentation, we define Aij D I.Ai D j /,
Nij .t/D AijNi .t/, and Yij .t/D AijYi .t/.
The quantity that we would like to infer in the comparison of two treatments (the ACE) is the differ-
ence in restricted mean lifetimes had all subjects in the population received treatment AD 1 as opposed
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to that had all subjects received AD 0. Specifically, denoting the potential (counterfactual) lifetime of a
subject if, possibly contrary to fact, he or she received treatment A D j by T j ; j D 0; 1, the restricted
mean lifetime for treatment A D j is j D Efmin.T j ; L/g, and the treatment effect can be contrasted
through the difference, ı D 1  0. It can be shown that restricted mean lifetime can be represented
as the area under the survival curve up to L, j D
R L
0 S
j .t/dt , where Sj .t/ is the marginal survival
function of T j . Therefore, treatment-specific restricted mean lifetimes and their difference represent a
cumulative measure of treatment effects. Throughout this article, we will make the stable unit treatment
value assumption [23, 24], which assumes that there is no interference between subjects and that the
observed survival time T for a subject receiving treatment AD j is equal to his or her potential lifetime
under the treatment j ; that is, T D AT 1 C .1  A/T 0. This assumption usually holds in a study with
no interference between subjects, as in the application we will consider. However, this assumption may
not hold, for example, in studies involving infectious disease as subjects interfere with each other and a
subject’s potential response under one treatment may be influenced by treatments other subjects receive.
The ACE, ı, is defined in terms of potential outcomes, which are not observed for all subjects.
Nevertheless, inference on the hypothetical quantity ı has to be based on observed data. In observational
data, the distribution of baseline covariatesZ among subjects in one group is possibly different from that
in the other group; or, equivalently, Z is not independent of A. If these covariates also predict potential
survival times, that is, Z is not independent of .T 0; T 1/, then both treatment difference and differences
in Z contribute to the observed difference in survival times between two groups; that is, the effect of
treatment on survival is confounded by imbalance in covariates. Put another way, treatment assignment
is not independent of the potential lifetimes due to their mutual correlation with covariates Z, also
referred to as confounders. This nonindependence introduces some difficulty in making causal inference
based on observational data, in contrast with randomized study where by design treatment assignment is
independent of potential lifetimes. A key assumption that allows causal inference on observational
data possible is that, conditional on Z, treatment assignment can be viewed as random in the sense
that it is independent of potential lifetimes; that is, A ?? .T 0; T 1/jZ. This assumption, required
by both the Chen and Tsiatis [10] method and the IPTW method of Wei [15], is referred to as the
‘strong ignorability’ assumption of treatment [17] or the ‘no unmeasured confounders’ assumption [12].
Note that this condition is also well studied in the economics and social science literature; for example,
[25, 26]. This assumption states that the dependence of treatment assignment on the potential outcomes
can be completely eliminated by the observed variablesZ. This assumption cannot be tested statistically
and can only be justified based on knowledge on the subject matter. In medical applications, treatment
decisions made by patients or their caregivers are usually based on information available at the time of
the decision making, such as demographics, comorbidities, severity, and past treatments of the subjects.
If such information is also captured in the data at hand, then this assumption is plausible.
In the next two paragraphs, we describe the Chen and Tsiatis method [10] and the IPTW method
of Wei [15], in order to later establish the relationship between each of these two methods and our
proposed method. Much of the notation introduced here will be needed later in the development of
the proposed method. The method of Chen and Tsiatis [10] removes confounding by first estimating
the treatment effect conditional on covariates Z. This part is straightforward because, conditional on
Z, treatment A can be viewed as randomly assigned. The conditional treatment effect measures the
difference in survival had subjects with covariates Z D ´ been assigned to A D 1 versus A D 0,
because f .T jA D j;Z D ´/ D f .T j jA D j;Z D ´/ D f .T j jZ D ´/ for j D 0; 1,
where f denotes ‘distribution of’ and the two equalities are due to the stable unit treatment value
assumption and no unmeasured confounders assumptions, respectively. Note that this result implies
P.T j > t jZ/ D P.T > t jA D j;Z/, which relates the conditional survival functions of potential
lifetimes to those of the observed lifetimes. Next, the ACE of A can be estimated by the average of the
conditional effects across the distribution of Z. Specifically, the Chen and Tsiatis method [10] posits
treatment-stratified Cox models [2] for T given .A;Z/,
ij .t/ .t jAi D j;Zi /D 0j .t/e
ˇT
j
Zi ; j D 0; 1; (1)
where .t jA;Z/ denotes the conditional hazard function given A and Z, and 0j .t/ are unspecified
treatment-specific baseline hazard functions. Inference on this model can be carried out by standard
survival analysis techniques. For example, ˇj can be estimated by the maximum partial likelihood
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estimator, b̌j [2, 27], whereas the baseline cumulative hazard function ƒ0j .t/  R t0 0j .u/du can be
consistently estimated by the Breslow estimator [28], denoted by bƒ0j .t/  R t0 PniD1 dNij .t/Pn










ebƒi1.t/  ebƒi0.t/dt , where ebƒij .t/ estimates the conditional survival
function P.Ti > t jAi D j;Zi /, with bƒij .t/ D eb̌Tj Zibƒ0j .t/. Finally, the average causal treatment
effect ı is estimated by averaging the conditional treatment effects across all Zi for i D 1; : : : ; n;






ebƒi1.t/  ebƒi0.t/dt . Note that n1PniD1 ebƒij .t/ estimates the marginal
survival function Sj .t/, and therefore Qı is also the integrated difference in estimated marginal
survival functions.
Instead of going through the treatment effect (and treatment-specific survival functions) conditional
on covariates, a different strategy is to estimate the average treatment effect directly through weighted
nonparametric estimators. In particular, the IPTW method [15] removes confounding by building up the
whole population that could have received the treatment, say,AD j , by inverse weighting the individuals
in group j with the probability of being in that group conditional on covariates. For example, if a subject
in treatment j has covariates Z D ´ and the probability of receiving the treatment P.A D j jZ D ´/,
then this subject actually represents 1=P.A D j jZ D ´/ individuals in the population of interest that
could have received the treatment and inverse weighting by this probability builds up the whole
population. Specifically, as marginal survival function can be estimated through the Nelson–Aalen
estimator of cumulative hazard function, the IPTW estimator for the marginal cumulative hazard function
of T j , ƒj .t/, can be viewed as a weighted Nelson–Aalen estimator; that is,






b Yi .t/ ; (2)
where wij
b  D I.Ai D j /=pij b  and pij b  is an estimator of P.Ai D j jZi /. Note that if the
weights, wij , are set to 1, then (2) reduces the usual Nelson–Aalen estimator of the cumulative hazard
function of T . If, instead, pij
b  is set to 1, then (2) reduces to the Nelson–Aalen estimator conditional
on each treatment. The probability P.Ai D j jZi / can be estimated by fitting a logistic regression model,
which assumes
logitfP.Ai D 1jZi /g D 
TXi ; (3)
whereXi includes an intercept and (possibly transformed) elements ofZi and logit.u/D logfu=.1u/g.
The Chen and Tsiatis [10] method builds models for survival time, and the resulting estimators for
Sj .t/; j D 0; 1; and ı are consistent for the true ACE if the assumed model (1) is correct. The IPTW
method builds a logistic model for treatment assignment, and the resulting estimators are consistent if
the assumed logistic model (3) is correct. In our proposed method, we propose to build models for both
the treatment assignment and survival time. The strategy is to attempt to either model the treatment
assignment correctly, allowing one to balance the distribution of covariates between treatments , or
to model the survival process correctly. If at least one of the models is correct, then the ACE can be
estimated consistently. Therefore, in the following discussions, we will refer to models (1) and (3) as
working models as they are not necessarily believed to be true. As the IPTW method, the proposed
method estimates treatment effect through estimating the marginal cumulative hazard functions, ƒj .t/.










bƒij .u/C n1PniD1 hwij b nebƒCj .u/Yij .u/ ebƒij .u/oi ;
(4)
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where bƒCj .u/ is the Nelson–Aalen estimator of the treatment-specific cumulative hazard function
(given AD j ) of C ,








with NCij .t/ D Aij I.Ui 6 t; i D 0/. Consequently, one can estimate Sj .t/ by bSj .t/ D ebƒj .t/, and
j by bj D R L0 bSj .u/du. Finally, the proposed estimator for ı is given bybı Db1 b0.
Before introducing the main theorem regarding asymptotic properties of the proposed estimators,
let us first heuristically explain how to understand this method and why it is expected to possess the
double-robust property. Note that Kang and Schafer [20] provided an exposition of double-robust




our proposed method estimates ƒj .t/ by estimating Sj .u/ and dSj .u/, respectively. Specifically, the
denominator inside the integral in (4) estimates Sj .u/ and the numerator estimates dSj .u/. Consider-
ing the denominator, the first term, n1
Pn
iD1 e
bƒij .u/, is the Chen and Tsiatis estimator of Sj .u/ and, as
explained earlier, is an average of estimators of the conditional survival functions P.Ti > ujAi D j;Zi /
across i D 1; : : : ; n. Suppose hypothetically that every subject in the population received treatment j
and, in addition, that censoring does not exist. In this setting, I.Ti > u/ would serve as the response,
such that the residual for each subject at time u, in the fit of model (1), is given by I.Ti > u/ ebƒij .u/.
If the model for survival time is correctly specified, on average the residuals are close to zero; other-
wise, the average of residuals estimates the bias of the Chen and Tsiatis estimator. In reality, because
the subjects who actually received treatment j are not representative of the whole population as a result
of lack of randomization, the average of residuals among those who actually received A D j does
not directly estimate the bias. Applying the idea of the IPTW method, it is easy to see that the bias
can be consistently estimated from residuals on those who are actually in group j by inverse weight-
ing their contributions by the corresponding probability of being in group j . In addition, in reality,
even for subjects in group j , I.Ti > u/, and correspondingly the residuals, are not observed for all
of them because of censoring, and instead one only observes Yi .u/. A solution to this is that one fur-
ther weights Yi .u/ by the probability of not being censored. Therefore, the bias can be estimated by
the second term in the denominator, that is, n1
Pn
iD1wij
b ˚ebƒCj .u/Yi .u/ ebƒij .u/, where ebƒCj .u/
estimates P.Ci > ujAi /1, the inverse probability of remaining uncensored as of time u for group
Ai D j . To summarize, if model (1) is correct, the first term of the denominator estimates Sj .u/ and the
second term estimates zero; if model (1) is possibly wrong but model (3) is correct, then the second
term estimates the bias of the first term and again the denominator consistently estimates Sj .u/.
Similarly, one can apply the same idea to the numerator, where the first term can be viewed as an
estimator for dSj .u/ and the second term is either estimator of zero or the bias of the first term. As
a result, the proposed estimator (4) is expected to be consistent for the true ACE if at least one of the
working models is correct.
We point out that the denominator of (4) is itself a double-robust estimator of Sj .u/. In our proposed
method, we do not use it directly because of the following considerations. The denominator can be





b ebƒCj .u/Yij .u/C n1PniD1 ˚1wij b ebƒij .u/, which
can be viewed as an augmented IPTW estimator of Sj .u/ with the first term being an IPTW
estimator and the second term as the augmentation term [29]. From this perspective, the denominator
builds upon the idea that EfYi .t/=P.Ci > t/g D P.Ti > t/ in a one-sample setting. Few practitioners
would use this method in the one-sample setting, in part because the resulting survival curve is not
monotone. The two most popular estimators in the one-sample setting are the Kaplan–Meier and
Nelson–Aalen estimators. Our method builds on the latter (and the Kaplan–Meier estimator is asymp-
totically equivalent to the Nelson–Aalen estimator). One can interpret our estimator as a modified
Nelson–Aalen estimator, with the modifications being to incorporate adjustment covariates and double
robustness. In addition, simulation studies show that using the denominator to estimate Sj .u/ directly
and then to estimate j may lead to considerably more bias than the proposed method in finite samples.
We summarize the asymptotic properties of the proposed estimators for j and ı with the following
theorem; we outline the proof in Appendix A.
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Theorem 1
Under conditions (a)–(f) listed in Appendix A, as n!1, if at least one of the working models specified
in (1) and (3) is correct, then bj converges in probability to j and n 12 bj  j  is asymptotically













/V 1./XifAij  pij .













































 and ˇj are the asymptotic limiting values of
b and b̌j , respectively, which may or may not equal
to the respective true values, depending on whether the corresponding assumed model is correct,
and dM ij .u/ D dNij .u/  Yij .u/dƒj .u/, with Bj .t Iˇ

j ; 
/, Fj .t Iˇj ; 
/, Gj .u; t Iˇj ; 
/,
Hj .u; t Iˇ

j ; 
/ defined in Appendix A. In addition, under the same conditions, bı converges in
probability to ı and n
1
2
bı  ı is asymptotically normal with mean zero and variance E.i1  i0/2.
In the aforementioned theorem, 'ij and ij seem complicated, and this is because it is stated without
explicitly assuming which working model is correctly specified. If one or both of the working models are
correctly specified, some of the terms in 'ij .t/ and ij are identically zero. For example, if the model (1)
is correct, then Bj

t Iˇj ; 


is equal to zero, and if the model (3) is the true model, then Fj






u; t Iˇj ; 






b2ij and n1PniD1 bi1bi02, respectively, wherebij is obtained by replacing limiting val-
ues in bij with their empirical counterparts. Although bij seems complicated, variance estimators can
actually be computed fast. SAS code illustrating the implementation of the proposed methods and the
variance estimators are available at http://www-personal.umich.edu/~mzhangst.
3. Simulation studies
In this section, we report results from simulation studies to evaluate the finite sample properties of the
proposed method. Results are based on 1000 Monte Carlo data sets with a sample size of nD 600.
In our simulated data, baseline covariates, Z1; Z2; Z3, are generated as normal with zero mean and
unit variance, and the correlation between Z1 and Z3 is 0.2. Each covariate is truncated at 4 and 4 to
be consistent with the regularity conditions listed in the Appendix. We then generated treatment indica-
tor A, according to a logistic regression model with logitfP.A D 1jZ/g D 0:5Z1  0:5Z2. Lifetime
T was generated as exponential with rate exp.2:5  1:5Z1  Z2  0:7Z3/ for treatment A D 0 and
exp.3Z1  0:9Z2 Z3/ for AD 1, respectively. Note that covariates Z1 and Z2 predict both treat-
ment assignment and survival time; therefore, they serve as confounders. Finally, we generated censoring
time C as exponential with rate exp.4:5/, which leads to approximately 25% censoring.
We compare the proposed method with the other methods introduced previously: the method of Chen
and Tsiatis [10], where one models the relationship of survival time to covariates by treatment-specific
Cox models; and the IPTW method of Wei [15] wherein one instead models the treatment assignment
with covariates using a logistic regression model. We evaluate each of the three estimators under settings
where the assumed models for survival time and treatment assignment are both correct or both incor-
rect or only one of them is correct. Specifically, for the T jA;Z model used in both the proposed and
Chen and Tsiatis [10] methods, we fit the correct model with the use of covariates .Z1; Z2; Z3/ for each
treatment, whereas we fit the incorrect model with the use of .Z1; Z3/. For the AjZ model used in the
proposed and the IPTW methods, we fit the correct model with the use of .Z1; Z2/, whereas we fit the
incorrect model with the use of Z1 only.
We estimated restricted mean lifetimes and their difference with L set to 10 and 20. Tables I and II
summarize results for estimating 1 and ı, respectively, and results for 0 are very similar and therefore
4260
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 4255–4268
M. ZHANG AND D. E. SCHAUBEL
Table I. Estimation of restricted mean lifetime for AD 1.
Method T model A model True Bias ESD ASE CP
LD 10
Proposed T T 6.849 0.002 0.201 0.193 0.942
T F 0:002 0.201 0.191 0.936
F T 0.002 0.205 0.196 0.937
F F 0:302 0.218 0.207 0.696
Denominator T T 0.028 0.205
T F 0.028 0.203
F T 0.029 0.209
F F 0:275 0.220
IPTW T 0.001 0.212 0.204 0.938
F 0:304 0.227 0.217 0.715
Chen and Tsiatis T 0.006 0.194 0.182 0.929
F 0:378 0.212 0.202 0.535
LD 20
Proposed T T 11.488 0.017 0.426 0.418 0.941
T F 0.008 0.422 0.410 0.938
F T 0.019 0.436 0.424 0.938
F F 0:686 0.453 0.438 0.652
Denominator T T 0.071 0.438
T F 0.071 0.427
F T 0.073 0.447
F F 0:630 0.457
IPTW T 0.016 0.454 0.449 0.946
F 0:690 0.474 0.463 0.684
Chen and Tsiatis T 0.021 0.410 0.395 0.938
F 0:810 0.438 0.426 0.533
T model indicates whether the model for T is true or false; A model indicates whether the
model for A is true or false. Bias is the Monte Carlo bias; ESD is the Monte Carlo standard
deviation of estimates; ASE is the Monte Carlo average of estimated standard errors; and CP is
the coverage probability of nominal 95% Wald confidence intervals.
Table II. Estimation of difference in restricted mean lifetimes.
Method T model A model True Bias ESD ASE CP
LD 10
Proposed T T 0.871 0:010 0.220 0.222 0.945
T F 0:022 0.217 0.228 0.953
F T 0:009 0.229 0.230 0.953
F F 0:686 0.260 0.259 0.245
IPTW T 0:013 0.248 0.256 0.960
F 0:690 0.279 0.285 0.329
Chen and Tsiatis T 0:004 0.208 0.204 0.943
F 0:726 0.256 0.256 0.188
LD 20
Proposed T T 1.682 0:009 0.454 0.453 0.946
T F 0:031 0.449 0.465 0.956
F T 0:005 0.470 0.467 0.953
F F 1:450 0.537 0.533 0.208
IPTW T 0:013 0.510 0.518 0.956
F 1:460 0.580 0.586 0.295
Chen and Tsiatis T 0.002 0.420 0.417 0.950
F 1:500 0.518 0.520 0.167
Entries as in Table I.
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Table III. Estimation of 5-year restricted mean lifetimes for DCD and
non-DCD kidney recipients and their difference.
Method b0 b1 ı p-value
IPTW of Wei 4.53 (0.057) 4.66 (0.068) 0.14 (0.088) 0.11
Chen and Tsiatis 4.50 (0.058) 4.66 (0.063) 0.16 (0.084) 0.06
Proposed 4.54 (0.057) 4.64 (0.068) 0.105 (0.088) 0.23
Standard error for each estimator is reported in parenthesis, and p-value is for
comparison of the mean restricted lifetimes between the two groups.
are not reported. Under all scenarios in which at least one of the working models is correctly specified,
the proposed estimators perform well, which is consistent with the purported double-robust property
of the proposed methods. Specifically, the proposed estimators are approximately unbiased for the true
parameters, and the 95% coverage probabilities achieve the nominal level. In contrast, the Chen and
Tsiatis and IPTW estimators perform well when the corresponding assumed model is correct; however,
large biases and small coverage probabilities are observed if the assumed model is incorrect.
As mentioned before, the denominator of (4) itself can be used as an estimator of the survival function
Sj .u/, which can be integrated to estimate j as well. Although asymptotically it is also double robust
in the sense that it is consistent for the truth when at least one of the working models is correct, our
simulation studies show that it has considerable larger bias than the proposed method (Table I).
4. Application
We applied the proposed methods to compare survival following deceased-donor kidney transplantation
among patients receiving a transplant through DCD versus the remainder (referred to here as non-DCD).
Eurotransplant, the Dutch Organ Transplant Registry and the Bureau of Geneaology, provided the
data. Specifically, Eurotransplant collected dates of registration on the kidney waiting list and, where
applicable, kidney transplantation. The Dutch Organ Transplant Registry provided information regarding
donor and recipient characteristics, as well as date of death. Data from the Bureau of Geneaology served
as the basis for verifying mortality information.
A total of n D 1139 patients were included in the analysis; 459 of whom received DCD kidney
transplants and 680 non-DCD transplants. The mean age at transplant was approximately 49 years, and
there were 88 observed deaths. As indicated previously, the groups being compared were DCD (j D 1)
versus non-DCD (j D 0). Adjustment covariates included age, sex, vascular disease (as a primary renal
diagnosis), panel reactive antibodies, expanded criteria donor, method of first dialysis, and years on
dialysis prior to transplant.
Under the proposed method (Table III), mean 5-year post-transplant survival time is estimated to beb1 D 4:64 years for the DCD group and b0 D 4:54 years for the non-DCD group, for difference ofbı D 0:10 years (p D 0:23). Therefore, there appears to be no difference in 5-year restricted mean
lifetime between recipients of DCD versus non-DCD kidneys. Results were similar based on the method
of Chen and Tsiatis [10] and the IPTW approach. In terms of precision, the lowest estimated standard
error was from the Chen and Tsiatis [10] method; because this method also estimated the largest differ-
encebı, it also yielded the lowest p-value, albeit still nonsignificant (p D 0:06). However, the validity of
this method requires the Cox model to be correct, unlike the proposed method, which only requires that
either the Cox model or the logistic model is correct.
5. Discussion
We propose a semiparametric double-robust estimator of the difference in treatment-specific restricted
mean survival time. The proposed method uses working models for treatment assignment and the death
hazard, and is consistent if at least one of the two working models is correct. We derive and show
asymptotic properties of the proposed estimator through simulation to be applicable to practical-sized
samples.
We compare our method with two existing methods through which differences in restricted mean
lifetimes can be estimated. The method of Chen and Tsiatis fits group-specific Cox models, then
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averages over the fitted values to obtain the ACE. The IPTW method uses inverse probability of treat-
ment weighting to estimate the ACE. Our proposed method can be viewed as a combination of Chen and
Tsiatis and the IPTW methods. We obtain consistency if the hazard regression model (from Chen and
Tsiatis method) or the group assignment model (used in IPTW method) are correctly specified.
A potential disadvantage of our method is that censoring times are assumed to be conditionally inde-
pendent of the death times, given only on the treatment indicator. The analogous assumption by Chen and
Tsiatis requires conditional independence given both treatment and adjustment covariates, a much less
stringent assumption. However, in many observational studies, it is quite reasonable to assume that the
adjustment covariates do not predict the censoring hazard. For example, in retrospective cohort studies
(e.g., particularly those based on registry or other precollected databases), censoring may be primarily
administrative; that is, the date the database was closed, a fixed calendar date that is external to the
patients, let alone their adjustment covariate pattern. In the IPTW method of Wei [15], the assumption
on the censoring distribution is the same as ours, although the IPTW method does not involve inverse
probability of censoring weighting. It should be noted that the IPTW method of Wei has been extended to
handle dependent censoring easily, under the ‘no-unmeasured-confounders-for-censoring’ assumption,
by inverse probability of censoring weighting, wherein one models the probability of censoring condi-
tional on baseline and/or time-dependent covariates and modifies the weight function wij
b  by further
weighting it by the inverse probability of remaining uncensored [30]. However, it is not straightforward
to extend the proposed method to accommodate dependent censoring because, in addition to modifying
the weight, one needs to modify the second term in both the numerator and the denominator of (4) as
well. Therefore, we do not consider this more general assumption on censoring in this article.
The application of the proposed methods implies that 5-year restricted mean post-transplant survival
time is no different for patients receiving a kidney transplant through DCD. The importance of this find-
ing is tied to the potential to increase the deceased-donor kidney pool by increasing DCD transplantation.
A natural question is whether a difference in restricted mean lifetime would be observed in the presence
of a similar study with longer post-transplant follow-up. In fact, in a large percentage of practical settings,
it would be preferable to use mean survival time (i.e., without inference being restricted to the .0; L
time interval). The development of robust methods for estimating and contrasting mean lifetime would
be valuable.
In this article, we considered estimation of the average causal treatment effect for the entire population
of interest. A different but also relevant quantity is the so-called average treatment effect for the treated
(ATT) [31], which targets the question of whether the treatment actually worked among treated subjects.
In terms of restricted mean lifetimes, the ATT is Efmin.T 1; L/ min.T 0; L/jA D 1g, and estimating
ATT requires a weaker ignorability assumption than the strong ignorability assumption assumed before;
that is, T 0??AjZ. We expect that the ideas underlying our proposed method could be extended to
estimate the ATT, which would be interesting for future research.
Appendix A.
A.1. Conditions and preparation results




















































for d D 0; 1; 2, where for a column vector a, a˝2 D aaT , a˝1 D a, and a˝0 D 1.
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We assume the following regularity conditions for i D 1; : : : ; n, and j D 0; 1:
(a) P.Ui > / > 0.
(b) Zi is bounded almost surely.
(c) ƒ0j ./ <1.
(d) ˇj is the unique solution toZ 
0
EfYij .t/Ziij .t/gdt 
Z 
0
Ńj .t Iˇ/EfYij .t/ij .t/gdt D 0;
and 	j .ˇ/ is positive definite.
(e)  is the unique maximizer to EfATX  log.1C e
TX /g, and V./ is positive definite.
(f) P.Ai D j jZi / is bounded away from 0.
With regard to model (1), it was shown that [32], under the assumed regularity conditions, b̌j p!ˇj ,



























































































b  D V 1./n 12 nX
iD1
XifAi  expit.
TXi /g C op.1/
for j D 0; 1 [33].











where dMCij .u/D dN
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If model (3) is correct, thenb p!  and pij b  p! pij ./D P.Aij D 1jZi /. Considering the denom-
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DEfP.Ti > ujAij D 1;Zi /g  S
j .t/:
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Similarly, one can obtain that the numerator converges in probability todSj .u/ uniformly in u 2 Œ0;  .
Combining results, we obtain that bƒj .t/ p!ƒj .t/ uniformly in t 2 Œ0;  . Therefore, by the continuous
mapping theorem, bSj .t/ p!Sj .t/ uniformly in t 2 Œ0;  , and in addition, bj andbı are consistent for
j and ı, respectively.
If model (1) is correct, then b̌j p! ˇj andbƒij .t/ p!ƒij .t/ uniformly in t 2 Œ0;  . The denominator




ebƒij .t/C n1 nX
iD1
wij





































Similarly, the numerator converges in probability to dSj .u/ uniformly in u 2 Œ0;  . Therefore, the
proposed estimators for ƒij .t/, j and ı are consistent for the true values when model (1) is correct.
Therefore, the proposed estimators are consistent for the true values when at least one of the working
models is correct.
A.3. Asymptotic normality
In the proofs of asymptotic normality, we do not specify explicitly which working model is correct,
and we denote that b̌j p!ˇj , bƒij .t/ p!ƒij .t/, andb p!. Let us first consider n 12 ˚bƒj .t/ƒj .t/,
which, as we will show, can be approximated by a scaled summation of independent and identically




nbƒj .t/ƒj .t/oDn 12 nbƒj 	t Ib;bƒij ;bƒCj 
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nbƒj t I ; ƒij ; ƒCj ƒj .t/o : (A.4)
By Taylor series expansion and substituting preparation results presented previously, after much
algebra, we obtain that
.5/D BTj




































































































Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 4255–4268
4265
M. ZHANG AND D. E. SCHAUBEL
.6/D F Tj

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where dM ij .u/D dNij .u/ Yij .u/dƒj .u/.
Combining the aforementioned results, we have shown that we can represent n
1










t Iˇj ; 
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When one of the working models is correct, using similar techniques used in proving consistency ofbƒij .t/ for ƒij .t/, it can be shown that 'ij .t/ has mean zero and are identically and independently
distributed across i D 1; : : : ; n.
Considering the estimation of j , n
1
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where ij D 
R L
0 S
j .u/'ij .u/du. When at least one of the two working models is correct, the ij
variates are independent and identically distributed with mean 0. Therefore, n
1
2
bj j  converges to a
normal distribution with mean 0 and varianceE.2ij /. It then follows that n
1
2
bıı is also asymptotically
normal with mean 0 and variance E.i1  i0/2 and n
1
2
bı  ıD n 12 PniD1.i1  i0/C op.1/.
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